Variant genotypes associated with reduced expression of RhCE antigens among Brazilian blood donors

Carregando...
Imagem de Miniatura
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2021
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Citação
TRANSFUSION, v.61, n.6, p.1923-1931, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background The genetic diversity of the RHCE gene locus has been explored in diverse populations of different racial backgrounds. Data referring to the diversity of RHCE encoding weakened expression of C, c, E, and e in multiethnic populations is still incomplete. Methods Samples from Brazilian blood donors presenting reduced expression of C, c, E, or e on gel method were selected for the study. All exons and flanking introns of RHCE were genotyped though direct Sanger sequencing for the included donors. Results Sixty-six donors were included: 23 with weak C, 22 with weak c, 6 with weak E, 14 with weak e, and 1 with weak c and E. Among the samples with weak C, the following altered RH*C were encountered: RHCE*CeMA (n = 3), RHCE*Ce941C (n = 1), and RHCE*CeVA (n = 1). RHD*D-CE(4-7)-D was detected in six cases, RHCE*CE was presumably present in five cases, and seven cases were unexplained. Two altered alleles underlay the weak c phenotype: RHCE*ceJAL (n = 20) and RHCE*ce340T (n = 2), and two altered RHCE justified weak e: RHCE*ceMO (n = 6) and RHCE*ceJAL (n = 8). Three variant RHCE were associated with weak E: RHCE*cEJU (n = 4), RHCE*cE382C (n = 1), and RHCE*cEIV (n = 1). The RHCE*cE905A justified one case of weak c and E. Conclusion We describe the distribution of RHCE variants found in association with weak expression of C, c, E, and e in blood donors of multiethnic origin, which differs in comparison to that previously reported for people of African or Caucasian descent.
Palavras-chave
genotyping, RHCE, RHD, weak antigen
Referências
  1. Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248
  2. Campos FCA, 2016, J CLIN LAB ANAL, V30, P845, DOI 10.1002/jcla.21946
  3. Alves VM, 2018, HEMATOL TRANSF CELL, V40, P389, DOI 10.1016/j.htct.2018.02.007
  4. Bugert P, 2009, TRANSFUSION, V49, P1793, DOI 10.1111/j.1537-2995.2009.02220.x
  5. Chou Stella T, 2010, Immunohematology, V26, P178
  6. Chou Stella T, 2009, Hematology Am Soc Hematol Educ Program, P178, DOI 10.1182/asheducation-2009.1.178
  7. Person RDD, 2020, HEMATOL TRANSF CELL, V42, P365, DOI 10.1016/j.htct.2019.08.004
  8. Denomme GA., 2000, MOL PROTOCOLS TRANSF
  9. Dezan Marcia R, 2020, Immunohematology, V36, P47
  10. Legler TJ, 2001, TRANSFUSION MED, V11, P383, DOI 10.1046/j.1365-3148.2001.00327.x
  11. Liu XM, 2004, DALTON T, P59, DOI 10.1039/b311980g
  12. Lomas-Francis C, 2009, TRANSFUSION, V49, P719, DOI 10.1111/j.1537-2995.2008.02025.x
  13. Maaskant-van Wijk PA, 1998, TRANSFUSION, V38, P1015, DOI 10.1046/j.1537-2995.1998.38111299056309.x
  14. Noizat-Pirenne F, 2002, BLOOD, V100, P4223, DOI 10.1182/blood-2002-01-0229
  15. Noizat-Pirenne F, 2001, BRIT J HAEMATOL, V113, P672, DOI 10.1046/j.1365-2141.2001.02802.x
  16. Perco P, 2003, TRANSFUSION, V43, P335, DOI 10.1046/j.1537-2995.2003.00313.x
  17. Pham BN, 2011, TRANSFUSION, V51, P1249, DOI 10.1111/j.1537-2995.2010.02970.x
  18. Schwarz JM, 2014, NAT METHODS, V11, P361, DOI 10.1038/nmeth.2890
  19. Singleton BK, 2000, BLOOD, V95, P12
  20. Tax MGHM, 2002, TRANSFUSION, V42, P634, DOI 10.1046/j.1537-2995.2002.00096.x
  21. Westhoff CM, 2004, TRANSFUSION, V44, P1663, DOI 10.1111/j.0041-1132.2004.04237.x
  22. Westhoff CM, 2004, TRANSFUSION, V44, P1047, DOI 10.1111/j.1537-2995.2004.04003.x
  23. Westhoff CM, 2007, TRANSFUSION, V47, p17S, DOI 10.1111/j.1537-2995.2007.01305.x
  24. Westhoff CM, 2013, TRANSFUSION, V53, P2983, DOI 10.1111/trf.12271
  25. Westhoff CM, 2009, TRANSFUSION, V49, P725, DOI 10.1111/j.1537-2995.2008.02034.x